[1] Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J. 2017;49(3):1700214. doi: 10.1183/13993003.00214-2017.
[2] ACIP. Prevention of Pneumococcal Disease – Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report [recommendations and reports series], 1997, 46:RR-8. https://www.cdc.gov/mmwr/pdf/rr/rr4608.pdf.
[3] Fang LW, Gao P, Bao HL, Tang X, Wang BH, Feng YJ, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med 2018;6(6):421 − 30. http://dx.doi.org/10.1016/S2213-2600(18)30103-6CrossRef
[4] Expert Group on Diagnosis and Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Chinese expert consensus on diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD)(2017 update). Int Respir J 2017;37(14):1041 − 57. http://dx.doi.org/10.3760/cma.j.issn.1673-436X.2017.14.001 (In Chinese). CrossRef
[5] World Health Organization. Training manual for Enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA) (007sp Version). https://www.vaccine.uab.edu/uploads/mdocs/ELISAProtocol(007sp).pdf. [2021-2-25].https://www.vaccine.uab.edu/uploads/mdocs/ELISAProtocol(007sp).pdf
[6] Lai CC, Lee LN, Yu CJ, Hsueh PR, Yang PC, Kuo SH, et al. Antibody responses to pneumococcal polysaccharide vaccine in Taiwanese patients with chronic obstructive pulmonary disease. J Formos Med Assoc 2007;106(3):196 − 203. http://dx.doi.org/10.1016/S0929-6646(09)60240-0CrossRef
[7] Chen M, Hisatomi Y, Furumoto A, Kawakami K, Masaki H, Nagatake T, et al. Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination. Clin Vaccine Immunol 2007;14(2):139 − 45. http://dx.doi.org/10.1128/CVI.00336-06CrossRef
[8] Ohshima N, Nagai H, Matsui H, Akashi S, Makino T, Akeda Y, et al. Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease. Vaccine 2014;32(10):1181 − 6. http://dx.doi.org/10.1016/j.vaccine.2013.09.060CrossRef
[9] de Roux A, Schmidt N, Rose M, Zielen S, Pletz M, Lode H. Immunogenity of the pneumococcal polysaccharide vaccine in COPD patients. The effect of systemic steroids. Respir Med 2004;98(12):1187 − 94. http://dx.doi.org/10.1016/j.rmed.2004.04.012CrossRef
[10] Huang LL, Wang L, Li H, Hu YS, Ru WP, Han WX, et al. A phase Ⅲ clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly. Hum Vaccin Immunother 2019;15(1):249 − 55. http://dx.doi.org/10.1080/21645515.2018.1509648CrossRef